Brian Salmons

List of Publications by Year
in descending order

127 papers	3,620 citations	136950 32 h-index	161849 54 g-index
132 all docs	132 docs citations	132 times ranked	2757 citing authors

#	Article	IF	Citations
1	Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet, The, 2001, 357, 1591-1592.	13.7	202
2	Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epsteinâ€“Barr Virus (EBV). Frontiers in Oncology, 2018, 8, 1.	2.8	175
3	Proviral load determination of different feline immunodeficiency virus isolates using real-time polymerase chain reaction: Influence of mismatches on quantification. Electrophoresis, 1999, 20, 291-299.	2.4	172
4	Targeting of Retroviral Vectors for Gene Therapy. Human Gene Therapy, 1993, 4, 129-141.	2.7	150
5	Development of Cellulose Sulfateâ€based Polyelectrolyte Complex Microcapsules for Medical Applications. Annals of the New York Academy of Sciences, 1999, 875, 46-63.	3.8	107
6	Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Therapy, 1998, 5, 1070-1078.	4.5	101
7	Expression of Antimicrobial Peptides Has an Antitumour Effect in Human Cells. Biochemical and Biophysical Research Communications, 1998, 242, 608-612.	2.1	95
8	Mouse Mammary Tumor Virus Infects Human Cells. Cancer Research, 2005, 65, 6651-6659.	0.9	92
9	A novel, mouse mammary tumor virus encoded protein with Rev-like properties. Virology, 2005, 337, 1-6.	2.4	89
10	A Mammary-Specific Promoter Directs Expression of Growth Hormone not only to the Mammary Gland, but also to Bergman Glia Cells in Transgenic Mice. Molecular Endocrinology, 1991, 5, 123-133.	3.7	83
11	Mouse Mammary Tumor Virus Integration Site Selection in Human and Mouse Genomes. Journal of Virology, 2008, 82, 1360-1367.	3.4	82
12	Current perspectives in the biology of mouse mammary tumour virus. Virus Research, 1987, 8, 81-102.	2.2	74
13	WPRE-mediated enhancement of gene expression is promoter and cell line specific. Gene, 2006, 372, 153-161.	2.2	63
14	Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR. Gene Therapy, 2000, 7, 458-463.	4.5	61
15	Mouse Mammary Tumor Virusâ€“like Sequences in Human Breast Cancer. Cancer Research, 2010, 70, 3576-3585.	0.9	58
16	Influence of Preassay and Sequence Variations on Viral Load Determination by a Multiplex Real-Time Reverse Transcriptaseâ€“Polymerase Chain Reaction for Feline Immunodeficiency Virus. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 8-20.	2.1	57
17	Rapid spread of mouse mammary tumor virus in cultured human breast cells. Retrovirology, 2007, 4, 73.	2.0	56
18	Endogenous superantigen expression controlled by a novel promoter in the MMTV long terminal repeat. Nature, 1993, 364, 154-158.	27.8	52

#	Article	IF	Citations
19	Rapid identification of viable retrovirus-transduced cells using the green fluorescent protein as a marker. Gene Therapy, 1997, 4, 1256-1260.	4.5	52
20	Influence of Preassay and Sequence Variations on Viral Load Determination by a Multiplex Real-Time Reverse Transcriptaseâ€"Polymerase Chain Reaction for Feline Immunodeficiency Virus. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 8-20.	2.1	51
21	Virus vector design in gene therapy. Trends in Molecular Medicine, 1995, 1, 410-417.	2.6	50
22	Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. Journal of Molecular Medicine, 1999, 77, 393-398.	3.9	50
23	Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation. Gene Therapy, 1999, 6, 737-748.	4.5	42
24	Rapid and sensitive detection of enhanced green fluorescent protein expression in paraffin sections by confocal laser scanning microscopy. The Histochemical Journal, 2000, 32, 99-103.	0.6	42
25	FMDVâ€"2A sequence and protein arrangement contribute to functionality of CYP2B1â€"reporter fusion protein. Analytical Biochemistry, 2005, 343, 116-124.	2.4	38
26	Rafts, anchors and viruses â€" A role for glycosylphosphatidylinositol anchored proteins in the modification of enveloped viruses and viral vectors. Virology, 2008, 382, 125-131.	2.4	38
27	naf, a trans-regulating negative-acting factor encoded within the mouse mammary tumor virus open reading frame region. Journal of Virology, 1990, 64, 6355-6359.	3.4	38
28	Xenotransplantation: is the risk of viral infection as great as we thought?. Trends in Molecular Medicine, 2000, 6, 199-208.	2.6	36
29	Novel clinical strategies for the treatment of pancreatic carcinoma. Trends in Molecular Medicine, 2001, 7, 30-37.	6.7	36
30	Mouse mammary tumor virus mediated transfer and expression of neomycin resistance to infected cultured cells. Virology, 1986, 155, 236-248.	2.4	35
31	Necrotic, rather than apoptotic, cell death caused by cytochrome P450â€"activated ifosfamide. Cancer Gene Therapy, 2001, 8, 220-230.	4.6	35
32	Development of retroviral vectors as safe, targeted gene delivery systems. Journal of Molecular Medicine, 1996, 74, 171-182.	3.9	34
33	Injection of Encapsulated Cells Producing an Ifosfamide-Activating Cytochrome P450 for Targeted Chemotherapy to Pancreatic Tumors. Annals of the New York Academy of Sciences, 1999, 880, 337-351.	3.8	32
34	Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century. Cancer Chemotherapy and Pharmacology, 2002, 49, 21-24.	2.3	32
35	Immunotherapy of a Viral Disease byin VivoProduction of Therapeutic Monoclonal Antibodies. Human Gene Therapy, 2000, 11, 1407-1415.	2.7	30
36	The cytotoxic activity of the bacteriophage Î»-holin protein reduces tumour growth rates in mammary cancer cell xenograft models. Journal of Gene Medicine, 2006, 8, 229-241.	2.8	30

#	Article	IF	Citations
37	Identification of the Rem-responsive element of mouse mammary tumor virus. Nucleic Acids Research, 2008, 36, 6284-6294.	14.5	30
38	Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Therapy, 2000, 7, 629-636.	4.6	29
39	Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors. Molecular Cancer Therapeutics, 2005, 4, 1786-1790.	4.1	29
40	Intratumoral Injection of Encapsulated Cells Producing an Oxazaphosphorine Activating Cytochrome P450 for Targeted Chemotherapy. Advances in Experimental Medicine and Biology, 1998, 451, 97-106.	1.6	28
41	Association of glycosylphosphatidylinositolâ€anchored protein with retroviral particles. FASEB Journal, 2008, 22, 2734-2739.	0.5	27
42	Revisiting a role for a mammary tumor retrovirus in human breast cancer. International Journal of Cancer, 2013, 133, 1530-1535.	5.1	27
43	CrFK Feline Kidney Cells Produce an RD114-Like Endogenous Virus That Can Package Murine Leukemia Virus-Based Vectors. Journal of Virology, 1998, 72, 7685-7687.	3.4	27
44	Effect of simian virus large T antigen expression on cell cycle control and apoptosis in rat pleural mesothelial cells exposed to DNA damaging agents. Oncogene, 1998, 16, 1041-1053.	5.9	26
45	Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors. Virology, 2005, 341, 1-11.	2.4	26
46	Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. Journal of Neuro-Oncology, 2011, 102, 59-69.	2.9	25
47	The endogenous mouse mammary tumour virus locus Mtv-8 contains a defective envelope gene. Virus Research, 1986, 4, 377-389.	2.2	24
48	Construction and characterization of a packaging cell line for MMTV-based conditional retroviral vectors. Biochemical and Biophysical Research Communications, 1989, 159, 1191-1198.	2.1	24
49	Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer. Pharmaceutics, 2014, 6, 447-466.	4.5	24
50	Human Endogenous Retroviral Long Terminal Repeat Sequences as Cell Type-Specific Promoters in Retroviral Vectors. Journal of Virology, 2009, 83, 12643-12650.	3.4	22
51	Recent developments linking retroviruses to human breast cancer: infectious agent, enemy within or both?. Journal of General Virology, 2014, 95, 2589-2593.	2.9	22
52	Cell targeting by murine retroviral vectors. Critical Reviews in Oncology/Hematology, 1998, 28, 7-30.	4.4	21
53	Novel treatments and therapies in development for pancreatic cancer. Expert Opinion on Investigational Drugs, 2002, 11, 769-786.	4.1	21
54	Encapsulated cells producing retroviral vectors forin vivogene transfer. Journal of Gene Medicine, 2002, 4, 150-160.	2.8	21

#	Article	IF	Citations
55	Multiple Modifications Allow High-Titer Production of Retroviral Vectors Carrying Heterologous Regulatory Elements. Journal of Virology, 2004, 78, 1384-1392.	3.4	21
56	Efficient protection of microorganisms for delivery to the intestinal tract by cellulose sulphate encapsulation. Microbial Cell Factories, 2020, 19, 216.	4.0	21
57	Expression of the oncogenes mil and ras abolishes the in vivo differentiation of mammary epithelial cells. Carcinogenesis, 1988, 9, 1849-1856.	2.8	20
58	Specific packaging of spliced retroviral vector transcripts lacking the Î¨-region. Biochemical and Biophysical Research Communications, 2002, 293, 239-246.	2.1	20
59	Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain. Gene Therapy, 2007, 14, 1330-1343.	4.5	20
60	Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial. Journal of Gastroenterology, 2003, 38 Suppl 15, 78-84.	5.1	20
61	Enhancement of the StreptoTag method for isolation of endogenously expressed proteins with complex RNA binding targets. Electrophoresis, 2006, 27, 1874-1877.	2.4	19
62	Small Agarose Microcapsules with Cell-Enclosing Hollow Core for Cell Therapy: Transplantation of Ifosfamide-Activating Cells to the Mice with Preestablished Subcutaneous Tumor. Cell Transplantation, 2009, 18, 933-939.	2.5	19
63	Negative regulatory element in the mammary specific whey acidic protein promoter. Journal of Cellular Biochemistry, 1994, 56, 245-261.	2.6	18
64	Intraarterial Instillation of Microencapsulated Cells in the Pancreatic Arteries in Pig. Annals of the New York Academy of Sciences, 1999, 880, 374-378.	3.8	18
65	The murine whey acidic protein promoter directs expression to human mammary tumors after retroviral transduction. Cancer Gene Therapy, 2002, 9, 421-431.	4.6	18
66	Tissue- and Tumor-Specific Targeting of Murine Leukemia Virus-Based Replication-Competent Retroviral Vectors. Journal of Virology, 2006, 80, 7070-7078.	3.4	18
67	Identification of three human sequences with viral superantigen-specific primers. Mammalian Genome, 1995, 6, 339-344.	2.2	17
68	Inducible expression of p21 WAF-1/CIP-1/SDI-1 from a promoter conversion retroviral vector. Journal of Molecular Medicine, 1997, 75, 820-828.	3.9	17
69	Construction and Characterization of a Hybrid Mouse Mammary Tumor Virus/Murine Leukemia Virus-Based Retroviral Vector. Journal of Virology, 1998, 72, 1699-1703.	3.4	17
70	Effects of Viral Strain, Transgene Position, and Target Cell Type on Replication Kinetics, Genomic Stability, and Transgene Expression of Replication-Competent Murine Leukemia Virus-Based Vectors. Journal of Virology, 2007, 81, 6973-6983.	3.4	15
71	Bacteriophage-encoded toxins: the ?-holin protein causes caspase-independent non-apoptotic cell death of eukaryotic cells. Cellular Microbiology, 2007, 9, 1753-1765.	2.1	15
72	Therapeutic Application of Cell Microencapsulation in Cancer. Advances in Experimental Medicine and Biology, 2010, 670, 92-103.	1.6	15

#	Article	IF	Citations
73	Protection of MLV Vector Particles from Human Complement. Biochemical and Biophysical Research Communications, 1999, 264, 1-5.	2.1	14
74	[35] Microencapsulation of genetically engineered cells for cancer therapy. Methods in Enzymology, 2002, 346, 603-618.	1.0	14
75	Encapsulated, genetically modified cells producing in vivo therapeutics. Current Opinion in Molecular Therapeutics, 2004, 6, 412-20.	2.8	14
76	Conditional expression of human TNF-Î±: A system for inducible cytotoxicity. International Journal of Cancer, 1994, 59, 103-107.	5.1	13
77	Effects of sequences of prokaryotic origin on titer and transgene expression in retroviral vectors. Virology, 2004, 330, 351-360.	2.4	13
78	Release characteristics of cellulose sulphate capsules and production of cytokines from encapsulated cells. International Journal of Pharmaceutics, 2018, 548, 15-22.	5.2	13
79	Phase I/II Clinical Trial of Encapsulated, Cytochrome P450 Expressing Cells as Local Activators of Cyclophosphamide to Treat Spontaneous Canine Tumours. PLoS ONE, 2014, 9, e102061.	2.5	13
80	Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy. Biochemical Pharmacology, 2006, 72, 893-901.	4.4	12
81	Mutations in the catalytic core or the C-terminus of murine leukemia virus (MLV) integrase disrupt virion infectivity and exert diverse effects on reverse transcription. Virology, 2007, 362, 50-59.	2.4	12
82	Evaluation of a Gene-Directed Enzyme-Product Therapy (GDEPT) in Human Pancreatic Tumor Cells and Their Use as In Vivo Models for Pancreatic Cancer. PLoS ONE, 2012, 7, e40611.	2.5	12
83	Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.. Acta Biochimica Polonica, 2019, 52, 601-607.	0.5	12
84	Encapsulated cells to focus the metabolic activation of anticancer drugs. Current Opinion in Molecular Therapeutics, 2010, 12, 450-60.	2.8	12
85	Retroviral vectors directed to predefined cell types for gene therapy. Biologicals, 1995, 23, 5-12.	1.4	11
86	Negative-acting factor and superantigen are separable activities of the mouse mammary tumor virus long terminal repeat.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2745-2749.	7.1	11
87	Intra-arterial instillation of microencapsulated, ifosfamide-activating cells in the pig pancreas for chemotherapeutic targeting. Pancreatology, 2003, 3, 55-63.	1.1	11
88	HIV-1 Rev can specifically interact with MMTV RNA and upregulate gene expression. Gene, 2005, 358, 17-30.	2.2	11
89	Semipermeable Cellulose Beads Allow Selective and Continuous Release of Small Extracellular Vesicles (sEV) From Encapsulated Cells. Frontiers in Pharmacology, 2020, 11, 679.	3.5	11
90	Modulation of Moloney Leukemia Virus Long Terminal Repeat Transcriptional Activity by the Murine CD4 Silencer in Retroviral Vectors. Virology, 2000, 276, 83-92.	2.4	10

#	Article	IF	Citations
91	Stem cell therapies: on track but suffer setback. Current Opinion in Molecular Therapeutics, 2009, 11, 360-3.	2.8	10
92	A Functional Eukaryotic Promoter Is Contained within the First Intron of the hGH-N Coding Region. Biochemical and Biophysical Research Communications, 1998, 247, 332-337.	2.1	9
93	JMM â€" Past and Present. Journal of Molecular Medicine, 2002, 80, 610-614.	3.9	9
94	Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors. Virology, 2006, 349, 121-133.	2.4	9
95	GMP Production of an Encapsulated Cell Therapy Product: Issues and Considerations. BioProcessing: Advances and Trends in Biological Product Development, 2007, 6, 37-44.	0.1	9
96	Characterization of a Human Cell Clone Expressing Cytochrome P450 for Safe Use in Human Somatic Cell Therapy. Annals of the New York Academy of Sciences, 1999, 880, 326-336.	3.8	8
97	Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches. Journal of Gene Medicine, 2008, 10, 113-122.	2.8	8
98	Mouse Mammary Tumor Virus Promoter-Containing Retroviral Promoter Conversion Vectors for Gene-Directed Enzyme Prodrug Therapy are Functional in Vitro and in Vivo. Journal of Biomedicine and Biotechnology, 2008, 2008, 1-10.	3.0	8
99	A modified procedure for replica plating of mammalian cells allowing selection of clones based on gene expression. BioTechniques, 1992, 12, 244-51.	1.8	8
100	A 470Âbp WAP-promoter fragment confers lactation independent, progesterone regulated mammary-specific gene expression in transgenic mice. Transgenic Research, 2005, 14, 145-158.	2.4	7
101	The 5â€² leader sequence of mouse mammary tumor virus enhances expression of the envelope and reporter genes. Journal of General Virology, 2012, 93, 308-318.	2.9	7
102	Superantigen Expression Is Driven by Both Mouse Mammary Tumor Virus Long Terminal Repeat-Associated Promoters in Transgenic Mice. Journal of Virology, 2000, 74, 2900-2902.	3.4	6
103	Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors. Journal of Gene Medicine, 2001, 3, 418-426.	2.8	6
104	Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors. BMC Molecular Biology, 2009, 10, 8.	3.0	6
105	Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits. Vaccine, 2018, 36, 6623-6630.	3.8	6
106	Encapsulated cells producing retroviral vectors for in vivo gene transfer. Journal of Gene Medicine, 2002, 4, 150-60.	2.8	5
107	Mapping of a mouse mammary tumor virus integration site by retroviral LTRâ€"arbitrary polymerase chain reaction. Virus Research, 1998, 54, 207-215.	2.2	4
108	Promoter Complex in the Central Part of the Mouse Mammary Tumor Virus Long Terminal Repeat. Journal of Virology, 2007, 81, 12572-12581.	3.4	4

#	Article	IF	Citations
109	MMTV accessory factor Naf affects cellular gene expression. Virology, 2006, 346, 139-150.	2.4	3
110	Mouse mammary tumor-like virus and human breast cancer. Breast Cancer Research and Treatment, 2010, 123, 907-909.	2.5	3
111	Combination Suicide Gene Therapy. , 2004, 90, 345-352.		2
112	Abundant authentic MMTV-Env production from a recombinant provirus lacking the major LTR promoter. Virology, 2005, 342, 201-214.	2.4	2
113	Quantification and Characterization of Autotransduction in Retroviral Vector Producer Cells. Human Gene Therapy, 2008, 19, 97-102.	2.7	2
114	Comment on Patel et al; â€œProtein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responsesâ€•Nanomedicine, 2015. 11(5): p. 1097-107. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 665-666.	3.3	2
115	Commentary regarding Gannon etÂal. â€œViral infections and breast cancer â€" A current perspectiveâ€• Cancer Letters, 2018, 424, 117-118.	7.2	2
116	Recipes for success?. Trends in Molecular Medicine, 2002, 8, 309.	6.7	1
117	Transgene Expression Facilitated by the v- <i>src</i> Splice Acceptor Can Impair Replication Kinetics and Lead to Genomic Instability of Rous Sarcoma Virus-Based Vectors. Journal of Virology, 2008, 82, 1610-1614.	3.4	1
118	Singapore R&D and globetrotting. Biotechnology Journal, 2009, 4, 179-185.	3.5	1
119	Commentary: With a little help from my enteric microbial friends. Frontiers in Microbiology, 2015, 6, 1029.	3.5	1
120	Tumorigenic Conversion of in vivo Differentiation Competent Mammary Cells by Introduction and Expression of ras or mil(raf) but not myc. , 1989, , 199-210.		1
121	Retroviral Vectors. , 0, , 35-60.		0
122	Phase I-study with encapsulated cells genetically modified to produce the ifosfamide activating cytochrome p 450 2Bl in patients with inoperable pancreatic carcinoma. Gastroenterology, 2000, 118, A522.	1.3	0
123	Viruses: friend or foe?. Trends in Molecular Medicine, 2001, 7, 185.	6.7	0
124	New developments at the <i>International Journal of Developmental Disabilities</i>. International Journal of Developmental Disabilities, 2014, 60, 1-2.	2.0	0
125	65 years and counting. International Journal of Developmental Disabilities, 2017, 63, 1-1.	2.0	0
126	Editorial: IJDD Past and Future Progress. International Journal of Developmental Disabilities, 2018, 64, 1-2.	2.0	0

#	Article	IF	Citations
127	Common Events in Mitogenic and Oncogenic Pathways. , 1988, , 109-121.		0